Skip to content
drillr.ai

JAZZ

Jazz Pharmaceuticals plc

NASDAQ · IEHealthcareBiotechnology
$243.47-1.64%

Price as of Jul 20, 2026

JAZZ news

Jazz Pharmaceuticals plc news

A server-rendered, paginated timeline of the latest available company news.

  1. Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

    Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 PR Newswire DUBLIN, July 20, 2026 DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update. Interested parties may register

    PR Newswire ·

  2. Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer

    Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer PR Newswire DUBLIN, June 12, 2026 For U.S. media and investors only DUBLIN, June 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca(®) (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC). The trial did no

    PR Newswire ·

  3. Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia

    Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia PR Newswire DUBLIN, June 4, 2026 Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN, June 4, 2026 /PRNew

    PR Newswire ·

  4. Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

    Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA PR Newswire DUBLIN, May 27, 2026 Expanded safety, subgroup, progression-free survival sensitivity and subsequent therapy analyses further characterize the consistency and durability of outcomes observed with zanidatamab-containing combinations in the first-line setting

    PR Newswire ·

  5. Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

    Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire DUBLIN, May 12, 2026 DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: * 2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m. ET * TD Cowen 7(th) Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026 at 2:00 p.m. ET

    PR Newswire ·

  6. Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

    Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA PR Newswire DUBLIN, April 27, 2026 Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) ac

    PR Newswire ·

  7. Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026

    Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 PR Newswire DUBLIN, April 21, 2026 DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET to discuss the results and provide a business and financial update. Interested parties may register for t

    PR Newswire ·

  8. Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting

    Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting PR Newswire DUBLIN, April 9, 2026 Six abstracts, including one oral presentation, underscore Jazz's ongoing commitment to generating real- world evidence addressing rare neurological disorders, including rare and severe forms of epilepsy and sleep disorders For U.S. media and investors only DUBL

    PR Newswire ·

  9. American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

    American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education PR Newswire CHICAGO, March 24, 2026 Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness CHICAGO, March 24, 2026 /PRNewswire/ -- The American Nutrition Association (ANA) today announced its initiative with Jazz Pharmaceuticals to pr

    PR Newswire ·

  10. Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026

    Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 PR Newswire DUBLIN, March 18, 2026 Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditionally activated IFN⍺2b cytokine For U.S. media and investors only DUBLIN, March 18, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) toda

    PR Newswire ·